Skip to content

Effect of controlled hypotension and protective hypotension on operative field quality and bleeding in nasal endoscopic surgery

Effect of controlled hypotension and protective hypotension on operative field quality and bleeding in nasal endoscopic surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064006
Enrollment
Unknown
Registered
2022-09-23
Start date
2022-09-23
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic sinusitis

Interventions

Control group:controlled hypotension
Experimental group:Protective hypotension

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years, both sexes; 2. Patients diagnosed with chronic sinusitis, with or without nasal septum deviation, with or without nasal polyps, with or without turbinate hypertrophy, with or without nasal mass, and planned to undergo nasal endoscopic sinus surgery to relieve nasal obstruction; 3. ASA classification I-II; 4. Volunteer to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Contraindications of controlled hypotension include hypovolemia and severe anemia, substantial lesions and dysfunction of vital organs, vascular lesions, and significant insufficiency of oxygen transport capacity of tissues and organs; 2. Preoperative coagulation dysfunction; 3. History of mental illness or cognitive impairment; 4. BMI is too high (> 30 kg/m2) or too low (< 18 kg/m2); 5. Patients with grade 2 or above hypertension, and patients with grade 1 hypertension whose preoperative blood pressure control is not ideal; 6. Allergic to intraoperative drugs; 7. Pregnant women; 8. Take any medication before operation that may affect the outcome and safety during operation; 9. Opioid dependence or opioid tolerance; 10. The investigator deemed it inappropriate to participate in the clinical trial.

Design outcomes

Secondary

MeasureTime frame
Intraoperative blood loss;Blood gas parameters;Blood gas parameters;Extubation time;Ramsay sedation score within 5 minutes after extubation;Length of stay in PACU;Incidence of adverse reactions within 24 hours after operation;Mini-mental State Examination score at 24 hours after surgery;

Primary

MeasureTime frame
Boezaart endoscopic field grading;

Countries

China

Contacts

Public ContactTao Meng

Qilu Hospital of Shandong University

mengtao@sdu.edu.cn+86 18560088229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026